Diabetes, Metabolic Syndrome & Cardiovascular Disease: Reshaping Tomorrow's Diabetes Market

This TriMark Publications report describes the specific market segment of the pharmaceutical market for diabetes and two of its related diseases, metabolic syndrome and cardiovascular disease. It begins with a textbook explanation of the biology underlying diabetes, and then it reviews and evaluates widely accepted pharmaceutical approaches to diabetes that are currently in use. Finally, market forecasts and an analysis of products in the worldwide prescriptions market will help the reader understand the significance of past developments and speculate on future possibilities about the market of diabetes therapies as an area of research and investment. The principal objectives of this report are to: 1) identify viable technology drivers through a comprehensive look at various platform technologies for diabetes, metabolic syndrome and cardiovascular disease; 2) provide a complete understanding of the leading diabetes tests that are used for disease prediction, screening, prognosis and monitoring, encompassing their basic principles and applications; 3) discover feasible market opportunities via an identification of high-growth applications in different therapeutic areas, with a focus on the largest and most rapidly expanding markets for diabetes, metabolic syndrome and cardiovascular disease; 4) focus on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including forecasts for growth; and 5) summarize the blood glucose testing market, including definitions, processes and trends. Market figures regarding the current value of the diabetes drug market are taken from the most recently available data of the global pharmaceutical industry. The following categories of diabetes drugs will be covered herein: 1) rapid-acting insulin; 2) short-activity insulin; 3) intermediate-acting insulin; 4) long-acting insulin; 5) ultra-long-acting insulin; 6) insulin mixtures; 7) sulfonylureas; 8) meglitinides; 9) biguanides; 10) thiazolidinediones; and 11) alpha-glucosidase inhibitors.

Pages: 161 Format: PDF Publication Date: 3 October 2005
View Table of Contents
Price: $1,999.00 / GBP999.50